Back to Search
Start Over
The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β2-adrenoceptor agonist in preclinical animal species.
- Source :
- Pharmacology Research & Perspectives; Aug2014, Vol. 2 Issue 4, pn/a-N.PAG, 12p
- Publication Year :
- 2014
-
Abstract
- Bronchodilators are a central therapy for symptom relief in respiratory diseases such as chronic obstructive pulmonary disease ( COPD) and asthma, with inhaled β<subscript>2</subscript>-adrenoceptor agonists and anticholinergics being the primary treatments available. The present studies evaluated the in vivo pharmacology of (R)-6-[[3-[[4-[5-[[2-Hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino]pent-1-ynyl]phenyl]carbamoyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide ( GS-5759), a novel bifunctional compound with both phosphodiesterase 4 ( PDE4) inhibitor and long-acting β<subscript>2</subscript>-adrenoceptor agonist ( LABA) activity, which has been optimized for inhalation delivery. GS-5759 dose-dependently inhibited pulmonary neutrophilia in a lipopolysaccharide ( LPS) aerosol challenge model of inflammation in rats with an ED<subscript>50</subscript> ≤ 10 μg/kg. GS-5759 was also a potent bronchodilator with an ED<subscript>50</subscript> of 0.09 μg/kg in guinea pigs and 3.4 μg/kg in dogs after methylcholine ( MCh) and ragweed challenges respectively. In cynomolgus monkeys, GS-5759 was dosed as a fine-particle dry powder and was efficacious in the same dose range in both MCh and LPS challenge models, with an ED<subscript>50</subscript> = 70 μg/kg for bronchodilation and ED<subscript>50</subscript> = 4.9 μg/kg for inhibition of LPS-induced pulmonary neutrophilia. In models to determine therapeutic index (T.I.), efficacy for bronchodilation was evaluated against increased heart rate and GS-5759 had a T.I. of 700 in guinea pigs and >31 in dogs. In a ferret model of emesis, no emesis was seen at doses several orders of magnitude greater than the ED<subscript>50</subscript> observed in the rat LPS inflammation model. GS-5759 is a bifunctional molecule developed for the treatment of COPD, which has both bronchodilator and anti-inflammatory activity and has the potential for combination as a triple therapy with a second compound, within a single inhalation device. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20521707
- Volume :
- 2
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Pharmacology Research & Perspectives
- Publication Type :
- Academic Journal
- Accession number :
- 96700955
- Full Text :
- https://doi.org/10.1002/prp2.46